夏宁邵 Xia, Ning-Shao
教授 博导

Professor, Xiamen University, Professor and Director, National Institute of Diagnostics and Vaccine Development in Infectious Diseases.
厦门大学生命科学学院、公共卫生学院教授、博导，国家传染病诊断试剂与疫苗工程技术研究中心主任，中国医学科学院结构疫苗学前沿技术创新单元（厦门大学）主任，国家药品监督管理局传染性疾病检测技术研究与评价重点实验室（厦门大学）主任。入选国家****、中国医学科学院学部委员。以第一完成人获国家技术发明二等奖、国家科技进步二等奖、中国专利金奖、全国创新争先奖、求是杰出科技成就集体奖、全国抗击新冠肺炎疫情先进集体。


Research Interesting
Research and development of recombinant antigen, vaccine and diagnostic kits related to medical virus, and their molecular biology and immunology study. To facilitate rapid response against newly emerged infectious diseases and forecast of new infections emerging.
医学病毒相关基因工程抗原、诊断试剂、疫苗、单克隆抗体等研发和产业化，以及相关病毒的分子生物学、免疫学基础研究。建立突发传染病应急反应和新发传染病预警技术体系。成功构建原核表达类病毒颗粒疫苗产业技术体系并突破多种检测试剂技术瓶颈，主持研制出全球首个戊肝疫苗、首个国产人乳头瘤病毒（HPV）疫苗、新一代国际“金标准”戊肝检测试剂、全球首个可指导用药的乙肝核心抗体定量试剂、全球首个艾滋抗体尿液自检试剂、全球首个新冠总抗体检测试剂，主持研制的鼻喷流感病毒载体新冠肺炎疫苗是全国新冠肺炎疫苗应急攻关的五条技术路线之一。


Selected Publications:
1. Xu LF#, Zheng QB#, Zhu R#, Yin ZC#, Yu H#, Lin Y, Wu YY, He MZ, Huang Y, Jiang YC, Sun H, Zha ZH, Yang HW, Huang QZ, Zhang DQ, Chen ZQ, Ye XZ, Han JL, Yang LS, Liu C, Que YQ, Fang MJ, Gu Y, Zhang J, Luo W, Zhou ZH*, Li SW*, Cheng T*, Xia NS*. Cryo-EM structures reveal the molecular basis of receptor-initiated coxsackievirus uncoating. Cell Host &Microbe. 2021; 29: 1-15. (IF=15.923)
2. He MZ#, Xu LF#, Zheng QB#, Zhu R#, Yin ZC#, Zha ZH, Lin Y, Yang LS, Huang Y, Ye XZ, Li SX, Hou WH, Wu YT, Han JL, Liu DX, Li ZK, Chen ZQ, Yu H, Que YQ, Wang YB, Yan XD, Zhang J, Gu Y, Zhou ZH*, Cheng T*, Li SW*, Xia NS*. Identification of Antibodies with Non-overlapping Neutralization Sites that Target Coxsackievirus A16. Cell Host &Microbe. 2020; 27(2): 249-261. (IF=15.923)
3. Wang W#, Zheng QB#, Pan DQ#, Yu H#, Fu WK, Liu J, He MZ, Zhu R, Cai YZ, Huang Y, Zha ZH, Chen ZQ, Ye XZ, Han JL, Que YQ, Wu T, Zhang J, Li SW*, Zhu H*, Zhou ZH*, Cheng T*, Xia NS*. Near-atomic cryo-electron microscopy structures of varicella-zoster virus capsids. Nature Microbiology. 2020; 5: 1542-1552. (IF=15.540)
4. Wang DN#, Liu XL#, Wei MX#, Qian CY, Song S, Chen J, Wang ZP, Xu Q, Yang YR, He MZ, Chi X, Huang SW, Li TT, Kong ZB, Zheng QB, Yu H, Wang YB, Zhao QJ, Zhang J, Xia NS*, Gu Y*, Li SW*. Rational design of a multi-valent human papillomavirus vaccine by capsomere-hybrid co-assembly of virus-like particles. Nature Communications. 2020; 11(1): 2841.(IF=12.121)
5. Wen GP#, He LL#, Tang ZM#, Wang SL#, Zhang X, Chen YZ, Lin XH, Liu C, Chen JX, Ying D, Chen ZH, Wang YB, Luo WX, Huang SJ, Li SW, Zhang J, Zheng ZZ*, Zhu J*, Xia NS*. Quantitative evaluation of protective antibody response induced by hepatitis E vaccine in humans. Nature Communications. 2020; 11(1): 3971. (IF=12.121)
6. Zhang YL#, Wang SJ#, Wu YT#, Hou WH#, Yuan LZ#, Sheng CG#, Wang J, Ye JH, Zheng QB, Ma J, Xu JJ, Wei M, Li ZL, Nian S, Xiong HL, Zhang L, Shi Y, Fu BR, Cao JL, Yang CL, Li ZY, Yang T, Liu L, Yu H, Hu JD, Ge SX, Chen YX, Zhang TY, Zhang J, Cheng T*, Yuan Q*, Xia NS*. Virus-Free and Live-Cell Visualizing SARS-CoV-2 Cell Entry for Studies of Neutralizing Antibodies and Compound Inhibitors. Small Methods. 2020; 5(2): **. (IF=12.130)
7. Zhang TY#, Chen HY#, Cao JL#, Xiong HL, Mo XB, Li TL, Kang XZ, Zhao JH, Yin B, Zhao X, Huang CH, Yuan Q*, Xue D*, Xia NS*, Yuan YA. Structural and functional analyses of hepatitis B virus X protein BH3-like domain and Bcl-xL interaction. Nature Communications. 2019; 10(1): 3192. (IF=12.121)
8. Liu X#, Liu C#, Zheng ZZ#, Chen SY, Pang X, Xiang XC, Tang JX, Ren E, Chen YZ, You M, Wang XY, Chen XY, Luo WX*, Liu G*, Xia NS*. Vesicular Antibodies: A Bioactive Multifunctional Combination Platform for Targeted Therapeutic Delivery and Cancer Immunotherapy. Advanced Materials. 2019; 31(17): e**. (IF=27.398)
9. Yuan LZ#, Jiang J#, Liu X#, Zhang YL, Zhang L, Xin JJ, Wu K, Li XL, Cao JL, Guo XR, Shi DY, Li J, Jiang LY, Sun SW, Wang TY, Hou WH, Zhang TY, Zhu H, Zhang J, Yuan Q, Cheng T*, Li J*, Xia NS*. HBV infection-induced liver cirrhosis development in dual-humanised mice with human bone mesenchymal stem cell transplantation. Gut. 2019; 68(11): 2044-2056. (IF=19.819)
10. Zhang TY#, Guo XR#, Wu YT#, Kang XZ, Zheng QB, Qi RY, Chen BB, Lan Y, Wei M, Wang SJ, Xiong HL, Cao JL, Zhang BH, Qiao XY, Huang XF, Wang YB, Fang MJ, Zhang YL, Cheng T, Chen YX, Zhao QJ, Li SW, Ge SX, Chen PJ, Zhang J*, Yuan Q*, Xia NS*. A unique B cell epitope-based particulate vaccine shows effective suppression of hepatitis B surface antigen in mice. Gut. 2020; 69(2): 343-354. (IF=19.819)
11. Qiao YL#*, Wu T#, Li RC#, Hu YM#, Wei LH#, Li CG#, Chen W#, Huang SJ, Zhao FH, Li MQ, Pan QJ, Zhang X, Li Q, Hong Y, Zhao C, Zhang WH, Li YP, Chu K, Li M, Jiang YF, Li J, Zhao H, Lin ZJ, Cui XL, Liu WY, Li CH, Guo DP, Ke LD, Wu X, Tang J, Gao GQ, Li BY, Zhao B, Zheng FX, Dai CH, Guo M, Zhao J, Su YY, Wang JZ, Zhu FC, Li SW, Pan HR, Li YM, Zhang J*, Xia NS*. Efficacy, safety, and immunogenicity of an Escherichia coli-produced bivalent human papillomavirus vaccine: An interim analysis of a randomized clinical trial. Journal of the National Cancer Institute. 2020; 112(2): 145-153. (IF=11.577)
12. Zheng QB,# Jiang J#, He MZ#, Zheng ZZ#, Yu H, Li TT, Xue WH, Tang ZM, Ying D, Li ZK, Song S, Liu XL, Wang KH, Zhang ZQ, Wang DN, Wang YB, Yan XD, Zhao QJ, Zhang J, Gu Y*, Li SW*, Xia NS*. Viral neutralization by antibody-imposed physical disruption. Proceedings of the National Academy of Sciences of the United States of America. 2019; 116(52): 26933-26940. (IF=9.412)
13. Zheng QB#, Zhu R#, Xu LF#, He MZ#, Yan XD#, Liu DX, Yin ZC, Wu YT, Li YC, Yang LS, Hou WH, Li SX, Li ZZ, Chen ZQ, Li ZH, Yu H, Gu Y, Zhang J, Baker TS, Zhou ZH, Graham BS*, Cheng T*, Li SW*, Xia NS*. Atomic structures of enterovirus D68 in complex with two monoclonal antibodies define distinct mechanisms of viral neutralization. Nature Microbiology. 2019; 4(1): 124-133. (IF=15.540)
14. Li ZH#, Song S#, He MZ#, Wang DN, Shi JJ, Liu XL, Li YB, Chi X, Wei SP, Yang YR, Wang ZP, Li JJ, Qian HL, Yu H, Zheng QB, Yan XD, Zhao QJ, Zhang J, Gu Y*, Li SW*, Xia NS*. Rational design of a triple-type human papillomavirus vaccine by compromising viral-type specificity. Nature Communications. 2018; 9: 5360. (IF=12.121)
15. Zhu R#, Xu LF#, Zheng QB#, Cui YX#, Li SW#, He MZ, Yin ZC, Liu DX, Li SX, Li ZZ, Chen ZQ, Yu H, Que YQ, Liu C, Kong Z, Zhang JB, Baker TS, Yan XD*, Zhou ZH*, Cheng T*, Xia NS*. Discovery and structural characterization of a therapeutic antibody against coxsackievirus A10. Science Advances. 2018; 4(9): eaat7459. (IF=13.117)
16. Shen CG, Chen JY, Li R, Zhang MY, Wang GS, Stegalkina S, Zhang LM, Chen J, Cao JL, Bi XJ, Anderson SF, Alefantis T, Zhang MW, Cai XY, Yang KY, Zheng QB, Fang MJ, Yu H, Luo WX, Zheng ZZ, Yuan Q, Zhang J, Shih JWK, Kleanthous H, Chen HL, Chen YX*, Xia NS*. A multimechanistic antibody targeting the receptor binding site potently cross-protects against influenza B viruses. Science Translational Medicine. 2017; 9(412): eaam5752. (IF=16.304)
17. Xu LF, Zheng QB, Li SW, He MZ, Wu YT, Li YC, Zhu R, Yu H, Hong QY, Jiang J, Li ZZ, Li SX, Zhao H, Yang LS, Hou WH, Wang W, Ye XZ, Zhang J, Baker TS, Cheng T*, Zhou ZH, Yan XD*, Xia NS*. Atomic structures of Coxsackievirus A6 and its complex with a neutralizing antibody. Nature Communications. 2017; 8: 505. (IF=12.121）
18. Tian DY, Battles MB, Moin SM, Chen M, Modjarrad K, Kumar A, Kanekiyo M, Graepel KW, Taher NM, Hotard AL, Moore ML, Zhao M, Zheng ZZ, Xia NS*, McLellan JS*, Graham BS*. Structural basis of respiratory syncytial virus subtype-dependent neutralization by an antibody targeting the fusion glycoprotein. Nature Communications. 2017; 8: 1877. (IF=12.121)
19. Zhang TY, Yuan Q*, Zhao JH, Zhang YL, Yuan LZ, Lan Y, Lo YC, Sun CP, Wu CR, Zhang JF, Zhang Y, Cao JL, Guo XR, Liu X, Mo XB, Luo WX, Cheng T, Chen YX, Tao MH, Shih JWK, Zhao QJ, Zhang J, Chen PJ, Yuan YA*, Xia NS*. Prolonged suppression of HBV in mice by a novel antibody that targets a unique epitope on hepatitis B surface antigen. Gut. 2016; 65(4): 658-671. (IF=19.819)
20. Fan R, Sun J, Yuan Q, Xie Q, Bai XF, Ning Q, Cheng J, Yu YY, Niu JQ, Shi GF, Wang H, Tan DM, Wan MB, Chen SJ, Xu M, Chen XY, Tang H, Sheng JF, Lu FM, Jia JD, Zhuang H, Xia NS*, Hou JL*, Chronic Hepatitis B SC. Baseline quantitative hepatitis B core antibody titre alone strongly predicts HBeAg seroconversion across chronic hepatitis B patients treated with peginterferon or nucleos(t)ide analogues. Gut. 2016; 65(2): 313-320. (IF=19.819)
21. Wang J, Shen T, Huang XB, Kumar GR, Chen XM, Zeng ZZ, Zhang RY, Chen R, Li T, Zhang TY, Yuan Q, Li PC, Huang Q, Colonno R, Jia JD, Hou JL, McCrae MA, Gao ZL*, Ren H*, Xia NS*, Zhuang H, Lu FM*. Serum Hepatitis B Virus Rna Is Encapsidated Pregenome Rna That May Be Associated with Persistence of Viral Infection and Rebound. Journal of Hepatology. 2016; 65: 700-710. (IF=20.582)
22. Zhang J*, Zhang XF, Huang SJ, Wu T, Hu YM, Wang ZZ, Wang H, Jiang HM, Wang YJ, Yan Q, Guo M, Liu XH, Li JX, Yang CL, Tang Q, Jiang RJ, Pan HR, Li YM, Shih JWK, Ng MH, Zhu FC*, Xia NS*. Long-Term Efficacy of a Hepatitis E Vaccine. New England Journal of Medicine. 2015; 372(10): 914-922. (IF=74.699)
23. Gu Y, Tang XH, Zhang X, Song CL, Zheng MH, Wang KH, Zhang J, Ng MH, Hew CL, Li SW*, Xia NS*, Sivaraman J*. Structural basis for the neutralization of hepatitis E virus by a cross-genotype antibody. Cell Research. 2015; 25(5): 604-620. (IF=20.507)
24. Yuan Q, Song LW, Liu CJ, Li Z, Liu PG, Huang CH, Yan Y, Ge SX, Wang YB, Peng CY，Zhang J*，Kao J-H，Chen D-S，Chen PJ*，Xia NS*. Quantitative hepatitis B core antibody level may help predict treatment response in chronic hepatitis B patients. Gut. 2013; 62(1): 182-184. (IF=19.819)
25. Wu T, Zhu FC, Huang SJ, Zhang XF, Wang ZZ, Zhang J, Xia NS*. Safety of hepatitis E vaccine for pregnant women: a preliminary analysis. Hepatology. 2012; 55(6): 2038. (IF=14.679)
26. Huang CH, Yuan Q, Chen PJ, Zhang YL, Chen CR, Zheng QB,Yeh SH, Yu H, Xue Y, Chen YX, Liu PG, Ge SX, Zhang J*, Xia NS*. Influence of mutations in hepatitis B virus surface protein on viral antigenicity and phenotype in occult HBV strains from blood donors. Journal of Hepatology. 2012; 57(4): 720-729. (IF=20.582)
27. Geng X, Huang CH, Qin Y, McCombs JE, Yuan Q, Harry BL, Palmer AE, Xia NS*,Xue D*. Hepatitis B virus X protein targets Bcl-2 proteins to increase intracellular calcium, required for virus replication and cell death induction. Proceedings of the National Academy of Sciences of the United States of America. 2012; 109(45): 18471-18476. (IF=9.412)
28. Tang XH, Yang CY, Gu Y, Song CL, Zhang X, Wang YB, Zhang J, Hew CL, Li SW*, Xia NS*, Sivaraman J*. Structural basis for the neutralization and genotype specificity of hepatitis E virus. Proceedings of the National Academy of Sciences of the United States of America. 2011; 25(108): 10266-10271. (IF=9.412)
29. Zhu FC#, Zhang J#, Zhang XF, Zhou C, Wang ZZ, Huang SJ, Wang H, Yang CL, Jiang HM, Cai JP, Wang YJ, Ai X, Hu YM, Tang QA, Yao X, Yan QA, Xian YL, Wu T, Li YM, Miao J, Ng MH, Shih JWK, Xia NS*. Efficacy and safety of a recombinant hepatitis E vaccine in healthy adults: a large-scale, randomised, double-blind placebo-controlled, phase 3 trial. Lancet. 2010; 376(9744): 895-902. (IF=60.390)
30. 夏宁邵，郑铁生．体外诊断产业技术．北京：人民卫生出版社，2018．